HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Characterization of long-term effector-memory T-cell responses in patients with resected high-risk melanoma receiving a melanoma Peptide vaccine.

Abstract
The authors determined whether long-term memory T cells could be detected in patients who received a multipeptide vaccine for high-risk resected melanoma. Five HLA-A*0201 patients received a vaccine that included the gp100(209-217) (210M) peptide with Montanide ISA 51. Peripheral blood mononuclear cells were obtained before therapy, after 6 months of vaccinations, and from 18 months to 36 months later. The presence of gp100 antigen-specific cytolytic T cells was measured by ELISPOT, tetramer and chromium release assays. Tetramer-positive CD8 cells were phenotyped by flow cytometry for markers including CD44, CD45RA, and CCR7. T-cell avidity and its evolution over time were examined in selected patients. Epitope spreading was analyzed by assessment of gp100(280-288) (288V) T cells. All patients exhibited a significant increase in tetramer-positive gp100-specific CD8 T cells that decayed at different rates over 18 to 36 months after vaccinations. Cells from all patients exhibited an effector-memory phenotype and were generally CD45 RA low/CCR7 negative and CD44 positive. Tetramer-positive cells declined over time in four of the five patients, but the proportion of tetramer-positive CD8 cells that secreted gamma-interferon rose, suggesting enrichment for effector cells. Epitope spreading for the gp100(280-288) (288V) epitope was detected. One patient maintained a population of 2.5% circulating gp100 tetramer-positive cells over 36 months. Avidity analysis showed no changes over time after induction of antigen-specific T cells. Vaccination with a heteroclitic melanoma antigen peptide with Montanide ISA 51 generated populations of circulating functional effector-memory T cells that were specific for gp100 and long-lived in the circulation for periods of 18 to 36 months after vaccination.
AuthorsBrian Chiong, Raymond Wong, Peter Lee, Joan Delto, Ronald Scotland, Roy Lau, Jeffrey Weber
JournalJournal of immunotherapy (Hagerstown, Md. : 1997) (J Immunother) 2004 Sep-Oct Vol. 27 Issue 5 Pg. 368-79 ISSN: 1524-9557 [Print] United States
PMID15314545 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S., Research Support, U.S. Gov't, P.H.S.)
CopyrightCopyright 2004 Lippincott Williams & Wilkins
Chemical References
  • Biomarkers
  • Cancer Vaccines
  • Epitopes
  • Membrane Glycoproteins
  • Oleic Acids
  • PMEL protein, human
  • Peptide Fragments
  • Peptides
  • gp100 Melanoma Antigen
  • gp100(280-288) melanoma antigen peptide
  • montanide ISA 51
  • Mannitol
  • Interferon-gamma
Topics
  • Adult
  • Biomarkers
  • CD8-Positive T-Lymphocytes (immunology)
  • Cancer Vaccines (immunology)
  • Clinical Trials as Topic
  • Epitopes (immunology)
  • Flow Cytometry
  • Humans
  • Immunologic Memory
  • Immunotherapy
  • Interferon-gamma (metabolism)
  • Mannitol (analogs & derivatives, immunology)
  • Melanoma (immunology, therapy)
  • Membrane Glycoproteins (immunology)
  • Middle Aged
  • Oleic Acids (immunology)
  • Peptide Fragments (immunology)
  • Peptides
  • Phenotype
  • Time Factors
  • gp100 Melanoma Antigen

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: